摘要
肾素-血管紧张素系统(RAS)调节剂包括肾素抑制剂、血管紧张素转化酶抑制剂、血管紧张素Ⅱ受体阻滞剂、血管紧张素Ⅱ受体激动剂和血管紧张素1-7等。本文通过检索1992年1月-2021年6月发表的相关文献,就RAS调节剂对抗肿瘤药的辅助作用进行汇总和分析。RAS调节剂可减轻抗肿瘤药的心脏毒性、血液学毒性、周围神经毒性等,并具有肾脏保护作用;其联合化疗药物可促进药物体内递送,联合靶向药物可抑制血管生成并改善旁路激活,联合免疫检查点抑制剂可增强肿瘤免疫反应进而提高抗肿瘤药的疗效。含RAS调节剂和抗肿瘤药的联合治疗模式有望减少抗肿瘤药的副作用、增强其疗效,并改善患者预后。
The regulators of renin-angiotensin system(RAS)include renin inhibitors,angiotensin converting enzyme inhibitors,angiotensinⅡreceptor blockers,angiotensinⅡreceptor agonists and angiotensin 1-7.This paper summarizes and analyzes the adjuvant effects of RAS regulators on antitumor drugs by searching the literature published from January 1992 to June2021.The regulators of RAS can reduce the cardiotoxicity,hematological toxicity and peripheral neurotoxicity of antitumor drugs,and has renal protective effect;the regulators of RAS combined with other chemotherapy drugs show favorable effects on promoting chemotherapeutic drugs delivery,improving anti-angiogenesis and bypass activation of targeted drugs,enhancing tumor immune response of immune checkpoint inhibitors,so as to improve therapeutic efficacy of antitumor drugs.The combination of RAS regulators with antitumor drugs is expected to reduce the side effects of antitumor drugs,enhance its efficacy and improve the prognosis of patients.
作者
徐诣芝
张劼
杨海燕
XU Yizhi;ZHANG Jie;YANG Haiyan(Dept.of Hematology,Chongqing General Hospital,Chongqing 400014,China;Dept.of Geriatrics,Chongqing General Hospital,Chongqing 400014,China)
出处
《中国药房》
CAS
北大核心
2022年第6期758-763,共6页
China Pharmacy
基金
重庆市基础研究与前沿探索项目(重庆市自然科学基金)(No.cstc2018jcyjAX0272)
重庆市科卫联合医学科研项目(No.2021MSXM066)
重庆市渝中区基础研究与前沿探索项目(No.20180158)。
